Where the UK pharma platform layer goes in the next two years is more predictable than most founders assume. Regulatory direction is signalled, AI capabilities are converging on specific use-cases, and the vertical-integration question is becoming the central strategic decision for platform vendors. This piece is a plain-English forecast for 2026 to 2028.
What the platform layer enabled — fewer barriers, faster compounding access
The platform layer has done two demonstrably useful things. It has lowered the launch barrier for new brands — three weeks instead of nine months. And it has democratised access to compounded preparations (specials) for clinicians and brands who would otherwise have struggled to find a reliable specials route. Multiple UK brands launched on white-label platforms have crossed 50k+ monthly active patients.
Categories that will mature next — diagnostics, mental health, paediatric, geriatric
Four categories look most likely to mature into platform-supported verticals over the next 24 months. Direct-to-patient diagnostics (blood markers, microbiome, hormonal panels). Mental health (talk therapy plus prescribing). Paediatric telehealth (highly nuanced regulatorily). Geriatric polypharmacy review (high social value, regulatory complexity). Not all will mature; the ones that do will be the ones with clean clinical pathways.
Vertical integration — where platforms expand vs stay focused
Platforms are diverging into two strategic camps. Vertically-integrated operators that own pharmacy, clinical network, and platform increasingly resemble healthcare conglomerates. Focused platforms that stay infrastructure-only and partner for clinical and pharmacy resemble fintech infrastructure plays. Both can work; the failure mode is platforms that drift between them without committing to either.
Regulation — what is likely to tighten, what is likely to loosen
The GPhC published guidance on remote pharmacy services in 2022 and updated it in 2024; further tightening is likely particularly around CD register reconciliation across remote operators. MHRA has signalled increased scrutiny of online medicines advertising in 2024 to 2025. CQC themed reviews are likely to repeat. Loosening, if any, is more likely on cross-border prescribing within the UK national health frameworks than on commercial advertising.
AI in clinical decision support — what is plausible by 2027
The realistic AI use-cases by 2027 are intake-flow optimisation, red-flag detection, post-consultation summarisation, and clinical-coding automation. The unrealistic ones are autonomous prescribing and unsupervised triage. AI-assisted clinical decision support tools must be certified as medical devices where they make clinical decisions, which constrains the autonomous direction. Expect tooling, not replacement.
What this means for founders, operators, and platform vendors
For brand founders: the platform layer is now mature enough to bet on; the strategic question is fit rather than viability. For clinic operators: the dispensing-partner question is now table stakes, not optional. For platform vendors: the next two years separate infrastructure-focused vendors who add value at scale from conglomerate-style vendors who absorb the value chain.
The next 24 months are about consolidation. The market is past the experimental phase. Operators who internalise that platforms are now mature infrastructure — not bets — will win disproportionately.
The next two years separate infrastructure-focused vendors from conglomerate-style vendors who absorb the value chain.
The future of UK pharma platforms is less dramatic than the recent past. It is becoming an industry rather than a story. That is good news for operators who run sustainable businesses and uncomfortable news for anyone whose strategy depends on hype.
